Travere Therapeutics Inc

NASDAQ:TVTX  
24.81
+0.08 (+0.32%)
Products, Regulatory

CSL Vifor And Travere Therapeutics Announce EMA To Review Conditional Marketing Authorization Application For Sparsentan For Treatment Of Iga Nephropathy

Published: 08/22/2022 11:11 GMT
Travere Therapeutics Inc (TVTX) - Csl Vifor and Travere Therapeutics Announce Ema Has Accepted for Review Conditional Marketing Authorization Application for Sparsentan for Treatment of Iga Nephropathy.
A Review Decision by European Medicines Agency (ema) is Expected in Second Half of 2023.
If Approved, Sparsentan Will Be a First-in-class Treatment to Address Significant Unmet Medical Need in Iga Nephropathy (igan) in Europe.
Csl Vifor and Travere Therapeutics, Inc. (nasdaq: Tvtx) Today Announced That Ema Has Accepted for Review Conditional Marketing Authorization (cma) Application for Sparsentan for Treatment of Igan, a Rare Kidney Disorder and a Leading Cause of End-stage Kidney Disease (eskd).